所有图片(1)

文件

A6478

(R,S)-AM1241

Name: (R,S)-AM1241
Brand: SIGMA

≥98% (HPLC), solid

别名:

(R,S)-3-(2-Iodo-5-nitrobenzoyl)-1-(1-methyl-2-piperidinylmethyl)-1H-indole

登录查看公司和协议定价

所有图片(1)

About This Item

经验公式（希尔记法）:

C₂₂H₂₂IN₃O₃

CAS号:

444912-48-5

分子量:

503.33

MDL號碼:

MFCD11045986

分類程式碼代碼:

12352200

PubChem物質ID:

24891092

NACRES:

NA.77

化驗

≥98% (HPLC)

形狀

solid

藥物控制

regulated under CDSA - not available from Sigma-Aldrich Canada

顏色

yellow

溶解度

DMSO: ~18 mg/mL at 60 °C

SMILES 字串

CN1CCCCC1Cn2cc(C(=O)c3cc(ccc3I)[N+]([O-])=O)c4ccccc24

InChI

1S/C22H22IN3O3/c1-24-11-5-4-6-16(24)13-25-14-19(17-7-2-3-8-21(17)25)22(27)18-12-15(26(28)29)9-10-20(18)23/h2-3,7-10,12,14,16H,4-6,11,13H2,1H3

InChI 密鑰

ZUHIXXCLLBMBDW-UHFFFAOYSA-N

應用

(R,S)-AM1241 has been used as a cannabinoid CB2 agonist:

to study its inhibitory effect on bone cancer-induced pain and bone loss
to study the effect of its interaction with 17βestradiol on proliferation activity in primary human osteoblasts
to evaluate the sites of CB2 mediated antinociception in vivo.

生化／生理作用

AM1241 acts as an antinociceptive agent in several animal pain models. It has a potential to delay disease progression in amyotrophic lateral sclerosis (ALS) mouse model. Intrathecal, intravenous or intraperitoneal administration of AM1241 reduces hyperalgesia and allodynia in neuropathic rats.

Selective CB₂ cannabinoid receptor agonist

象形圖

GHS08,GHS07

訊號詞

Danger

危險聲明

H315,H319,H334,H335

防範說明

P302 + P352 - P305 + P351 + P338

危險分類

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects.

Elizabeth J Rahn et al.

Pharmacology, biochemistry, and behavior, 98(4), 493-502 (2011-03-09)

Cannabinoid CB(2) agonists produce antinociception without central nervous system (CNS) side-effects. This study was designed to characterize the pharmacological and antinociceptive profile of AM1710, a CB(2) agonist from the cannabilactone class of cannabinoids. AM1710 did not exhibit off-target activity at

Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation.

A G Nackley et al.

Neuroscience, 119(3), 747-757 (2003-06-18)

Activation of cannabinoid CB(2) receptors attenuates thermal nociception in untreated animals while failing to produce centrally mediated effects such as hypothermia and catalepsy [Pain 93 (2001) 239]. The present study was conducted to test the hypothesis that activation of CB(2)

AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis

Kim K, et al.

European Journal of Pharmacology, 542(1-3), 100-105 (2006)

The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats

de Carvalho CR, et al.

Epilepsy Research, 127(2), 160-167 (2016)

A synergistic interaction of 17-$\beta$-estradiol with specific cannabinoid receptor type 2 antagonist/inverse agonist on proliferation activity in primary human osteoblasts

Hojnik M, et al.

Biomedical Reports, 3(4), 554-558 (2015)

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件